FDA Puts Hold on Vertex Hepatitis Study

July 26, 2013

By Bill Berkrot

(Reuters) - Vertex Pharmaceuticals Inc said U.S. health regulators placed a partial clinical hold on a mid-stage study of an experimental oral hepatitis C treatment because of potential liver problems.

Vertex said the U.S. Food and Drug Administration took the action after the Phase II study in Europe of its VX-135 in combination with the standard hepatitis drug ribavirin showed elevated liver enzymes in three patients taking the 400 milligram dose of its drug.

As a result of the hold on the U.S. clinical trial, the Massachusetts-based biotechnology company said it was unable to begin dosing patients in a planned U.S. study aimed at testing VX-135 at 200 mg.

"We are committed to continuing to work closely with the FDA to provide the data needed to support evaluation of a 200 mg dose of VX-135 in the U.S.," Robert Kauffman, Vertex's chief medical officer, said in a statement.

The 400 mg arm of the European study was discontinued and the patients' liver enzymes returned to what they had been prior to entering the trial, Vertex said.

A U.S. study evaluating 100 mgs of VX-135 was not affected, the company said.

VX-135 is also being studied at 100 mg and 200 mg in combination with Bristol-Myers Squibb Co's daclatasvir, a highly promising hepatitis drug from a different class of oral medicines.

Vertex also makes hepatitis C treatment Incivek (telaprevir). But that drug must be taken with the often difficult to tolerate injected drug interferon to provide high cure rates.

New all oral treatment regimens for hepatitis C hold promise of high cure rates without the need for interferon and the flu-like symptoms that come with it.

The first of those are expected to become available in 2014 from other companies and Vertex has been playing catch-up.

"With our ongoing studies in the U.S., Europe and now New Zealand with VX-135 and daclatasvir, our strategy in hepatitis C is unchanged - to develop an all-oral therapy that provides a high cure rate across multiple hepatitis C genotypes," Kauffman said.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: